IMEIK(SZ:300896) Xin Lang Cai Jing·2025-09-23 12:55Core Viewpoint - REGEN, a subsidiary of Aimeike Technology Development Co., Ltd., is involved in an arbitration dispute with Datuo Medical Devices (Shanghai) Co., Ltd. regarding a distribution contract, with the arbitration accepted by the Shenzhen International Arbitration Court on September 23, 2025, and the impact on Aimeike's profits remains uncertain [1]. Group 1 - REGEN received a notice of arbitration on August 13, 2025, regarding the distribution contract dispute initiated by Datuo, which was accepted by the court [1]. - On September 10, 2025, an emergency arbitrator made a decision on Datuo's request for interim measures [1]. - REGEN's counterclaim requests the termination of Datuo's exclusive agency rights for AestheFill products in mainland China, the cancellation of related agreements, and compensation for reasonable expenses incurred due to the arbitration [1]. Group 2 - Prior to this announcement, Aimeike and its subsidiaries had undisclosed small lawsuits and arbitration matters involving approximately 11.1581 million yuan, accounting for 0.14% of the company's most recent audited net assets [2]. - As of the announcement date, there are no undisclosed single case amounts exceeding 10% of the company's most recent audited net assets or absolute amounts over 10 million yuan [2]. - REGEN has engaged a professional legal team to handle the arbitration and will protect the legal rights of the company and its shareholders [2].